Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate changes in cytokine levels after intravitreal bevacizumab injection in patients with chronic central serous chorioretinopathy (CSC). Methods: In a prospective interventional trial, 12 eyes from 12 patients with chronic CSC and six eyes from six patients who underwent cataract surgery were included as controls. Patients diagnosed as with CSC received a single intravitreal injection of bevacizumab (1.25 mg/0.05 mL). Aqueous humor samples were collected from the patients and controls. Best-corrected visual acuity and foveal thickness were evaluated, and aqueous samples were obtained before and 4 weeks after injection. The aqueous concentrations of interleukin (IL)-6, IL-8, interferon-induced protein (IP)-10, monocyte chemotactic protein (MCP)-1, platelet-derived growth factor (PDGF)-AA, and vascular endothelial growth factor (VEGF) were measured using a multiplex bead assay. Results: After injection, the foveal thickness decreased significantly from 328.08 μm (range, 210–477 μm) to 283.91 μm (range, 168–356 μm; p = 0.048), but the best-corrected visual acuity was not significantly different (p = 0.066). The aqueous levels of IL-8 increased significantly from 3.3 pg/mL (range, 1.5–8.3 pg/mL) to 4.7 pg/mL (range, 2.2–11.6 pg/mL) at 4 weeks after the injection (p = 0.046). The aqueous levels of VEGF decreased significantly from 31.4 pg/mL (range, 17.0–53.3 pg/mL) to 15.2 pg/mL (range, 7.7–21.5 pg/mL; p < 0.01). No significant changes in levels of IL-6 (p = 0.455), IP-10 (p = 0.055), MCP-1 (p = 0.076), and PDGF-AA (p = 0.339) were noted 4 weeks after injection. Conclusions: In this study we found intravitreal bevacizumab injection decreased VEGF and increased IL-8 in the eyes of patients with chronic CSC. This study suggests the possibility that the pathogenesis of CSC may be related to abnormal circulation of the choroidal blood vessels through VEGF and IL-8 cytokine level changes.
Abstract
Purpose: This study aimed to investigate changes in cytokine levels after intravitreal bevacizumab injection in patients with chronic central serous chorioretinopathy (CSC). Methods: In a prospective interventional trial, 12 eyes from 12 patients with chronic CSC and six eyes from six patients who underwent cataract surgery were included as controls. Patients diagnosed as with CSC received a single intravitreal injection of bevacizumab (1.25 mg/0.05 mL). Aqueous humor samples were collected from the patients and controls. Best-corrected visual acuity and foveal thickness were evaluated, and aqueous samples were obtained before and 4 weeks after injection. The aqueous concentrations of interleukin (IL)-6, IL-8, interferon-induced protein (IP)-10, monocyte chemotactic protein (MCP)-1, platelet-derived growth factor (PDGF)-AA, and vascular endothelial growth factor (VEGF) were measured using a multiplex bead assay. Results: After injection, the foveal thickness decreased significantly from 328.08 μm (range, 210–477 μm) to 283.91 μm (range, 168–356 μm; p = 0.048), but the best-corrected visual acuity was not significantly different (p = 0.066). The aqueous levels of IL-8 increased significantly from 3.3 pg/mL (range, 1.5–8.3 pg/mL) to 4.7 pg/mL (range, 2.2–11.6 pg/mL) at 4 weeks after the injection (p = 0.046). The aqueous levels of VEGF decreased significantly from 31.4 pg/mL (range, 17.0–53.3 pg/mL) to 15.2 pg/mL (range, 7.7–21.5 pg/mL; p < 0.01). No significant changes in levels of IL-6 (p = 0.455), IP-10 (p = 0.055), MCP-1 (p = 0.076), and PDGF-AA (p = 0.339) were noted 4 weeks after injection. Conclusions: In this study we found intravitreal bevacizumab injection decreased VEGF and increased IL-8 in the eyes of patients with chronic CSC. This study suggests the possibility that the pathogenesis of CSC may be related to abnormal circulation of the choroidal blood vessels through VEGF and IL-8 cytokine level changes.
참고문헌 (35)
- Gass JD, "Pathogenesis of disciform detachment of the neuroepithelium", Am J Ophthalmol, 63(Suppl), pp.1~139 (1967)
- Jung SH, "Cytokine levels of the aqueous humour in central serous chorioretinopathy", Clin Exp Optom, 97, pp.264~269 (2014)
- Loo RH, "Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy", Retina, 22, pp.19~24 (2002)
- Burumcek E, "Laser photocoagulation for persistent central serous retinopathy : results of long-term follow-up", Ophthalmology, 104, pp.616~622 (1997)
- Taban M, "Chronic central serous chorioretinopathy : photodynamic therapy", Am J Ophthalmol, 137, pp.1073~1080 (2004)
- Chan WM, "Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy : one-year results of a prospective study", Retina, 28, pp.85~93 (2008)
- Torres-Soriano ME, "A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy(case reports)", Graefes Arch Clin Exp Ophthalmol, 246, pp.1235~1239 (2008)
- Schaal KB, "Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy", Eur J Ophthalmol, 19, pp.613~617 (2009)
- Seong HK, "Intravitreal bevacizumab to treat acute central serous chorioretinopathy : shortterm effect", Ophthalmologica, 223, pp.343~347 (2009)
- Lim SJ, "Intravitreal bevacizumab injection for central serous chorioretinopathy", Retina, 30, pp.100~106 (2010)
- Yu J, "Risk factors for persistent or recurrent central serous chorioretinopathy", J Ophthalmol, 2019, pp.5970659~ (2019)
- Nicholson B, "Central serous chorioretinopathy : update on pathophysiology and treatment", Surv Ophthalmol, 58, pp.103~126 (2013)
- Mrejen S, "Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy", Ophthalmology, 126, pp.576~588 (2019)
- Cardillo Piccolino F, "Photodynamic therapy for chronic central serous chorioretinopathy", Retina, 23, pp.752~763 (2003)
- Chan WM, "Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin : a novel treatment at the primary disease level", Br J Ophthalmol, 87, pp.1453~1458 (2003)
- Colucciello M, "Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy", Retina, 26, pp.239~242 (2006)
- Lim JW, "The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy", Graefes Arch Clin Exp Ophthalmol, 249, pp.969~974 (2011)
- Lim JW, "Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy", Retina, 30, pp.1465~1471 (2010)
- Mehany SA, "Role of Avastin in management of central serous chorioretinopathy", Saudi J Ophthalmol, 24, pp.69~75 (2010)
- Morteza Entezari, "Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy", Korean Journal of Ophthalmology, 26(2), pp.139~142 (2012), 대한안과학회
- Iacono P, "Central serous chorioretinopathy treatments : a mini review", Ophthalmic Res, 55, pp.76~83 (2015)
- Chung YR, "Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy:meta-analysis and review", Eye(Lond), 27, pp.1339~1346 (2013)
- 박상욱, "Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results", Korean Journal of Ophthalmology, 28(4), pp.306~313 (2014), 대한안과학회
- Lee YS, "Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis", Br J Cancer, 106, pp.1833~1841 (2012)
- Kramer M, "Inflammatory reaction in acute retinal artery occlusion : cytokine levels in aqueous humor and serum", Ocul Immunol Inflamm, 13, pp.305~310 (2005)
- Yuuki T, "Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy", J Diabetes Complications, 15, pp.257~259 (2001)
- Paroli MP, "Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis", Eur J Ophthalmol, 17, pp.938~942 (2007)
- Harada A, "Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases", Mol Med Today, 2, pp.482~489 (1996)
- Deng Z, "TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer", Oncol Rep, 35, pp.359~365 (2016)
- Funatsu H, "Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema", Ophthalmology, 110, pp.1690~1696 (2003)
- Terao N, "Association of upregulated angiogenic cytokines with choroidal abnormalities in chronic central serous chorioretinopathy", Invest Ophthalmol Vis Sci, 59, pp.5924~5931 (2018)
- Ide N, "Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells", Hypertens Res, 31, pp.1257~1267 (2008)
- Meleth AD, "Serum inflammatory markers in diabetic retinopathy", Invest Ophthalmol Vis Sci, 46, pp.4295~4301 (2005)
- Shahar J, "Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab(Avastin)", Retina, 26, pp.262~269 (2006)
- Zhou LB, "Blocking VEGF signaling augments interleukin-8 secretion via MEK", ERK, 2 axis in human retinal pigment epithelial cells, pp.Int J Ophthalmol, 2020[DOI]